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Abstract: A series of new derivatives (5–29) of marine-derived bostrycin (1) were 
synthesized. The in vitro cytotoxic activities of all compounds were evaluated against 
MCF-7, MDA-MB-435, A549, HepG2, HCT-116 and MCF-10A cells using the MTT 
method. The compounds 7, 8, 22, 23, 25, 28 and 29 of the total showed comparable activity 
to epirubicin, the positive control, against the tested cancer cell lines. However, these 
compounds also exhibited cytotoxicity towards MCF-10A cells. The structure-activity 
relationship (SAR) of bostrycin derivatives was also discussed based on the obtained 
experimental data. 
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1. Introduction 
A variety of tetrahydroanthraquinone derivatives isolated from fungi [1–6] and plants [7] display 
various biological properties including antibacterial [3,6], antiprotozoal [8], phytotoxic [9] and 
cytotoxic activities [7,10]. Previous studies have shown that tetrahydroanthraquinone derivatives can 
inhibit the growth of cultured cells of Nicotiana rustica, and act as a potent stimulator of NADH 
oxidation in mitochondria and electron acceptors in an enzyme preparation of diaphorase [11]. 
Bostrycin (1, Figure 1), a natural tetrahydroanthraquinone compound, was isolated from the mangrove 
endophytic fungus No. 1403 collected from the South China Sea, as well as three bostrycin analogues 
(2–4, Figure 1) [12–14]. The originally proposed structure of bostrycin was identified by interpretation 
of spectral date (IR, UV, MS, 
1H NMR, 
13C NMR) [15–17], and then revised by Kelly and his   
co-workers [18] on the basis of the total synthesis of (+/−)-bostrycin and an X-ray crystal structure of 
the O-isopropylidene derivative. Subsequently, Larsen’s group [19] revised the absolute configuration 
of (−)-bostrycin through an elegant asymmetric synthesis of (+)-bostrycin. Our recent studies have 
shown that bostrycin has broad-spectrum antitumor activity [13,14,20,21]. Bostrycin can induce 
apoptosis of breast cancer cells through Akt/FOXO pathway, revealing it is a potent apoptosis   
inducer [20]. Bostrycin also showed lethal cytotoxicity to yeast cells by inducing apoptosis via an 
Aif1p-dependent, mitochondria-mediated apoptotic pathway [22]. Chen et al. [23] reported that 
bostrycin can inhibit proliferation of human lung carcinoma A549 cells via downregulation of the 
P13K/Akt. The pharmacological and toxicological profiles of bostrycin, as well as its in vivo antitumor 
efficacy, provided us with reasonable optimism that bostrycin could become a promising Akt inhibitor 
and anticancer drug candidate [20]. However, there have been few studies on the structural 
modification and structure-activity relationship (SAR) of bostrycin. Therefore, our research interest 
was focused on the modification of bostrycin and its SAR study with the intention of discovering novel 
antitumor agents from bostrycin derivatives. In this work, a series of bostrycin derivatives (5–29, 
Schemes 1–3) were synthesized with variation at positions 2, 3, 6 and 7 of the tetrahydroanthraquinone 
core. All these natural and synthesized compounds were evaluated for their cytotoxic activities against 
five human cancer cell lines MCF-7, MDA-MB-435, A549, HepG2 and HCT-116, and one 
immortalized human breast epithelial cell line MCF-10A. The SAR was further discussed on the basis 
of the obtained experimental data. As we expected, some of the modified compounds exhibited strong 
anticancer activities against the tested cancer cells, with superior potency over the parent bostrycin. Mar. Drugs 2012, 10  
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Figure 1. Structures of bostrycin (1), deoxybostrycin (2), nigrosporin B (3) and 
austrocortinin (4). 
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Scheme 1. Synthesis of 2,3-ketal/substituted bostrycin derivatives 5–8. 
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Scheme 2. Synthesis of 6-aminosubstituted bostrycin derivatives 9–22. 
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Scheme 3. Synthesis of 6,7-thiosubstituted bostrycin derivatives 23–29. 
 
2. Results and Discussion 
2.1. Chemistry 
Bostrycin (1) and its analogues (2–4, Figure 1) were isolated from the mangrove endophytic fungus 
No. 1403 collected from the South China Sea [12–14]. To explore the effects of hydroxyl groups at C-2 
and C-3 positions in bostrycin on antitumor activity, 2,3-ketal/substituted derivatives 5–8 were 
synthesized (Scheme 1). Bostrycin was reacted with 2,2-dimethoxypropane, 3-methyl-2-butenal and Mar. Drugs 2012, 10  
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polyoxymethylene in the presence of 1 equiv of p-toluenesulfonic acid (TsOH) at room temperature, 
2,3-ketal derivatives 5, 6 and 7 were obtained respectively. Moreover, treatment of Bostrycin with 
triphosgene in the presence of pyridine at −10 °C gave compound 8. 
The nucleophilic substitution of 2,3-dichloro-1,4-naphthoquinone by various nucleophiles was 
employed as the key reaction [24–27] to afford the structurally diverse derivatives with variation on 
the C-6 and C-7 positions of bostrycin. We studied the reaction of bostrycin with various amines 
(Scheme 2) and thiols/dithiols (Scheme 3). When bostrycin was treated with various types of amines at 
room temperature or 50 °C using methanol as solvent, a series of alkyl/arylamino derivatives 9–22 
were obtained (Scheme 2). In addition, the preparation of compounds 15 and 16 required a longer 
reaction time and higher temperature presumably due to the low reactivity of the aryl amines used. 
This reaction involved a typical nucleophilic displacement of the methoxy group in bostrycin (1) with 
various amines as nucleophiles. The possible mechanism is depicted as in Figure 2. When bostrycin 
reacted with various thiols and dithiols at 0–5 °C in the presence of triethylamine, a series of alkylthio 
disubstituted derivatives 23–29 (at C-6 and C-7) were obtained (Scheme 3). We deduced the dithio 
substituted compounds might be obtained through two steps. Firstly, nucleophilic addition of an 
alkylthio anion to C-6 followed by elimination of the methoxy group to give a monothio substituted 
bostrycin intermediate. However, the second addition of another mole of alkylthio anion to C-7 can be 
smoothly carried out due to its strong nucleophilicity, and then tautomerization between the ketone and 
enol configuration takes place. Subsequently, the diphenol structure was oxidized to the target quinone 
structure (23–29) by the remaining large amount of starting material bostrycin and/or oxygen from the 
air. The detailed mechanism is proposed as in Figure 3. The structures of all the compounds were 
established on the basis of their nuclear magnetic resonance spectra (
1H NMR, 
13C NMR) and mass 
spectra (ESI, EI). 
Figure 2. Nucleophilic substitution of bostrycin and amines. 
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Figure 3. Nucleophilic substitution of bostrycin and thiols. 
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2.2. Biological Activity 
All compounds were evaluated for their in vitro cytotoxic activity against five human cancer cell 
lines including human breast MCF-7, human breast MDA-MB-435, human lung A549, human liver 
HepG2 and human colon HCT-116, and compared with their effects on the immortalized human breast 
epithelial cell line MCF-10A by MTT assay [20,28] using epirubicin (an anticancer drug used widely 
in the clinic [29–31]) as positive control. The results are summarized in Table 1 and discussed below. 
Table 1. Cytotoxicity of compounds 1–29 against MCF-7, MDA-MB-435, A549, HepG2, 
HCT-116 and MCF-10A cells (IC50, μM) 
a. 
Compound/ 
Cell Line 
MCF-7 
b MDA-MB-435 
b A549 
b HepG2 
b HCT-116 
b MCF-10A 
b 
1  2.18 ± 0.14  2.82 ± 0.17  2.63 ± 0.33  7.71 ± 0.72  4.78 ± 0.03  14.08 ± 0.58 
2  2.69 ± 0.31  3.19 ± 0.92  4.49 ± 0.13  9.99 ± 0.55  5.69 ± 0.25  13.83 ± 0.76 
3  6.19 ± 0.60  2.91 ± 0.18  4.72 ± 0.17  31.01 ± 0.71  4.70 ± 0.39  28.63 ± 0.91 Mar. Drugs 2012, 10  
 
938
Table 1. Cont. 
4  >50  41.59 ± 2.63  >50  >50  >50  >50 
5  6.87 ± 0.33  5.96 ± 0.21  4.25 ± 0.16  36.95 ± 1.97  11.03 ± 1.35  18.11±1.30 
6  7.99 ± 0.09  11.67 ± 1.18  5.50 ± 0.24  22.34 ± 2.89  7.83 ± 0.32  34.15 ± 0.85 
7  2.52 ± 0.26  4.25 ± 0.57  0.78 ± 0.04  4.58 ± 0.50  3.06 ± 0.10  4.79 ± 0.52 
8  1.59 ± 0.16  1.26 ± 0.12  0.52 ± 0.02  3.32 ± 0.58  2.92 ± 0.06  21.72 ± 1.45 
9  3.58 ± 0.65  >50  31.07 ± 1.94  22.35 ± 1.16  34.24 ± 1.27  >50 
10  13.97 ± 0.98  >50  21.50 ± 1.43  18.00 ± 0.60  26.38 ± 0.89  >50 
11  1.08 ± 0.21  >50  25.14 ± 0.74  35.68 ± 1.29  36.46 ± 0.53  >50 
12  4.87 ± 0.23  4.25 ± 0.75  3.74 ± 0.67  12.91 ± 0.96  4.06 ± 0.65  Nt 
c 
13  35.55 ± 1.40  >50  >50  32.16 ± 2.43  35.93 ± 1.13  >50 
14  >50 >50  >50  >50  >50  >50 
15  3.72 ± 0.27  10.32 ± 0.45  4.87 ± 0.43  >50  4.84 ± 0.25  41.60 ± 0.51 
16  39.44 ± 0.68  36.41 ± 2.08  41.44 ± 2.86  30.31 ± 1.63  43.27 ± 1.56  Nt 
c 
17  28.66 ± 2.37  40.37 ± 1.49  21.30 ± 2.02  >50  20.63 ± 0.37  19.79 ± 0.63 
18  9.17 ± 0.28  25.56 ± 1.71  15.18 ± 0.42  >50  13.63 ± 1.85  27.69 ± 0.93 
19  7.94 ± 0.26  7.86 ± 1.20  6.25 ± 0.43  >50  4.92 ± 0.38  7.50 ± 0.69 
20  3.14 ± 0.31  4.04 ± 0.35  3.16 ± 0.23  1.99 ± 0.17  2.81 ± 0.31  Nt 
c 
21  4.62 ± 0.44  6.38 ± 0.47  3.06 ± 0.46  6.09 ± 1.14  3.25 ± 0.67  Nt 
c 
22  4.81 ± 0.40  0.95 ± 0.13  0.76 ± 0.03  6.61 ± 1.12  0.75 ± 0.05  Nt 
c 
23  0.71 ± 0.01  0.76 ± 0.06  4.07 ± 0.51  6.90 ± 0.26  0.95 ± 0.06  14.79 ± 0.96 
24  2.45 ± 0.48  7.05 ± 0.56  4.06 ± 0.42  4.03 ± 0.13  3.25 ± 0.54  30.64 ± 2.54 
25  2.60 ± 0.45  10.64 ± 1.11  0.71 ± 0.01  3.33 ± 0.66  0.74 ± 0.10  34.96 ± 1.94 
26  14.42 ± 0.42  13.33 ± 0.20  26.12 ± 3.15  22.66 ± 1.95  11.95 ± 1.53  Nt 
c 
27  6.01 ± 0.39  3.19 ± 0.15  7.31 ± 0.58  3.18 ± 0.75  3.08 ± 0.35  Nt 
c 
28  0.57 ± 0.04  0.63 ± 0.45  0.37 ± 0.04  0.82 ± 0.01  0.68 ± 0.08  0.81 ± 0.11 
29  3.18 ± 0.22  0.55 ± 0.11  4.06 ± 0.35  2.55 ± 0.55  0.73 ± 0.02  Nt 
c 
epirubicin 
d  0.96 ± 0.08  0.56 ± 0.06  0.61 ± 0.05  0.96 ± 0.02  0.48 ± 0.03  0.48 ± 0.08 
a IC50 values are taken as means ± standard deviation from three independent experiments; 
b MCF-7, human breast cancer 
cell line; MDA-MB-435, human breast cancer cell line; A549, human lung cancer cell line; HepG2, human liver cancer 
cell line; HCT-116, human colon cancer cell line; MCF-10A, the immortalized human breast epithelial cell line;   
c Nt = not tested; 
d Used as a positive control. 
Bostrycin analogues 2 and 3 exhibited comparable cytotoxic activity to bostrycin against all tested 
cancer cell lines, except for compound 3  for  HepG2 cells, while compound 4 lost potency   
(IC50 > 50 μM). The activity profiles suggested that the hydroxyl groups at C-1 and/or C-10 in 
bostrycin were not essential for the cytotoxic activity whereas the tetrahydroaromatic ring with the 
polyhydroxyl groups was the key pharmacophore of bostrycin. 
These bostrycin derivatives were tested on inhibitory activity against the growth of several tumor 
cell lines along with one immortalized human breast epithelial cell line. As shown in Table 1, some 
modified compounds exhibited much better activity than bostrycin, and even displayed comparable 
activity to epirubicin against the cancer cells tested. However, the majority of compounds were also 
highly cytotoxic to the immortalized human breast epithelial cells. For example, the activities of 
compounds 7 (IC50 = 0.78 μM) and 8 (IC50 = 0.52 μM) against A549 cells have comparable activity to 
those of epirubicin (IC50 = 0.61 μM). A similar potency profile was observed with compounds 22 Mar. Drugs 2012, 10  
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(against MDA-MB-435, A549 and HCT-116 cells), 23 (against MCF-7, MDA-MB-435 and HCT-116 
cells), 25 (against A549 and HCT-116 cells) and 29  (against MDA-MB-435 and HCT-116 cells). 
Significantly, compound 28 showed broad-spectrum antitumor activity, with equal potency to 
epirubicin against MCF-7, MDA-MB-435, A549, HepG2 and HCT-116 cells lines with IC50 values of 
0.57, 0.63, 0.37, 0.82 and 0.68 μM, which were 3.8-, 4.5-, 7.1-, 9.4- and 7.0-fold more active than 
bostrycin (with IC50 value of 2.18, 2.82, 2.63, 7.71 and 4.78 μM), respectively. However, these 
compounds also exerted marked cytotoxic effect on immortalized human breast epithelial cells. 
Moreover, compounds 7 and 8 exhibited excellent selective activity for A549 cells over other cancer 
cells, and the cytotoxic activity of compounds 9 and 11 against MCF-7 cell line was much stronger 
than for other kinds of cancer cell lines. Compound 28 (IC50 = 0.57 μM) possessed the most potent 
activity against HepG2 cells. The SAR analysis revealed that: (1) 2,3-ketal derivatives 5 and 6 showed 
a slight decrease in antiproliferative activity compared to bostrycin. However, compound 8 displayed 
stronger activity, which indicated that the protection of C-2 and C-3 with a dioxylcarbonyl group was 
favorable for activity; (2) Compound 7 with a hydroxymethyl group at C-1 position and a methylene 
group at C-2 and C-3 positions, showed comparable activity to epirubicin for A549 cells;   
(3) Secondary heterocyclic amine-substituted derivatives  (20–22) possessed  more  potency  than 
primary amine-substituted derivatives (9–11 and 13–19) against all cancer cells except for MCF-7 
cells. The results suggested that derivatives bearing tertiary amino groups have better activity than 
derivatives bearing secondary amino groups; (4) Although compounds 9 and 11 displayed significantly 
decreased potency compared to that of bostrycin against five human cancer cells except for MCF-7 
cells, they had improved selectivity for MCF-7 cells over other cancer cells; (5) Compared to 
alkylamino derivatives 9–11, longer alkylamino substituents seems beneficial for anticancer activity, 
as exemplified by compound 12 with significantly improved activity against MDA-MB-435, A549 and 
HCT-116 cells; (6) Phenylamino-substituted derivative 15 exhibited better antiproliferative activity 
than all other primary amine-substituted  derivatives against A549 and HCT-116 cells, except for 
compound  12; (7) Compared to derivatives 20,  21, 4-phenylpiperidine-substituted derivative 22 
exhibited comparable activity to epirubicin against MDA-MB-435, A549 and HCT-116 cells, which 
indicated that a larger group substituted at the 6-piperidine position may be helpful for activity;   
(8) Disubstituted thiol derivatives 23–25 and 27 showed strong cytotoxic activity against five human 
cancer cell lines with IC50 values of 0.71–10.64 μM; (9) The length of the carbon chain of alkylthio 
substituents also affected the antiproliferative activity of the compounds against different cancer cells. 
For example, for compounds 23–25, the activity to inhibit the growth of MCF-7 and MDA-MB-435 
cells was decreased as the length of the carbon chain of alkylthio substituents was increased. However, 
for A549 and HepG2 cells, the order of activity was reversed; (10) Dithiol-substituted derivatives 28, 
29 displayed potent cytotoxic activity against five human cancer cell lines, especially, compound 28 
which generally exhibited comparable activity to epirubicin against five human cancer cell lines. Mar. Drugs 2012, 10  
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3. Experimental Section 
3.1. Chemistry 
Reagents and solvents were commercially available. Solvents were dried and purified using 
standard procedures prior to use. Melting points were measured on an X-4 micromelting point 
apparatus and were uncorrected. IR spectra were measured on a Bruker Vector 22 spectrophotometer 
using KBr pellets. NMR spectra were determined on a Varian Inova-500 NB spectrometer or Bruker 
AV-400 NB spectrometer in CDCl3 or DMSO-d6 using TMS as internal standard, and coupling 
constants (J) are in Hz. EI mass spectra were recorded on a DSQ mass spectrometer and ESI mass 
spectra were obtained on a LCQ DECA XP LC-MS mass spectrometer. Flash column chromatography 
was performed with silica gel (Qing dao Ocean Chemical Factory, 200–300 mesh) eluted with 
petroleum ether–dichloromethane or dichloromethane–methanol, and C18 reversed phase silica gel 
(Welch Material, Inc., 45 μm) eluted with methanol–water. 
3.2. Preparation of Bostrycin (1), Deoxybostrycin (2), Nigrosporin B (3) and Austrocortinin (4) 
Bostrycin (1) and its analogues (2–4) were isolated from the secondary metabolites of the mangrove 
endophytic fungus Nigrospora sp. No. 1403 collected from the South China Sea according to literature 
procedures [12–14]. 
Bostrycin (1). Red solid (MeOH); mp: 252–254 °C; [α]
25 
D  −272 (c 2.2 × 10
−4, MeOH); IR (KBr):  
νmax = 3532, 3512, 3480, 3367, 3031, 2991, 2934, 2893, 2857, 1595, 1478, 1460, 1441 cm
−1; 
1H NMR 
(400 MHz, DMSO-d6):  δ 13.39 (s, 1H, 9-OH), 12.63 (s, 1H, 10-OH), 6.48 (s, 1H, 7-H), 5.23   
(d, J = 4.9 Hz, 1H, 1-OH), 4.93 (d, J = 4.8 Hz, 1H, 2-OH), 4.75 (t, J = 4.9 Hz, 1H, 1-H), 4.48 (s, 1H,  
3-OH), 3.92 (s, 3H, 6-OMe), 3.53 (t, J = 4.8 Hz, 1H, 2-H), 2.74 (d, J = 18.2 Hz, 1H, 4-Hb), 2.67  
(d, J = 18.2 Hz, 1H, 4-Ha), 1.23 (s, 3H, 3-CH3); 
13C NMR (125 MHz, DMSO-d6): δ 184.29 (C-8), 
177.49 (C-5), 160.45 (C-9), 160.22 (C-6), 160.07 (C-10), 139.44 (C-9a), 136.80 (C-4a), 109.85 and 
109.51 (C-7 and C-10a), 107.49 (C-8a), 76.40 (C-2), 69.33 (C-3), 68.30 (C-1), 56.97 (6-OMe), 34.89 
(C-4), 25.67 (3-CH3); EIMS m/z 336 [M]
+ (23), 318 (17), 303 (9), 289 (19), 271 (12), 263 (100), 
247 (11), 234 (35), 216 (16). 
Deoxybostrycin (2). Red solid (MeOH); mp: 224–225 °C; [α]
25 
D  +90.9 (c 1.1 × 10
−4, MeOH);   
1H NMR (300 MHz, DMSO-d6): δ 13.18 (s, 1H, 9-OH), 12.62 (s, 1H, 10-OH), 6.42 (s, 1H, 7-H), 4.82 
(d, J = 5.1 Hz, 1H, 2-OH), 4.48 (s, 1H, 3-OH), 3.88 (s, 3H, 6-OMe), 3.61 (dt, J = 7.3, 5.1 Hz, 1H, 2-H), 
2.82 (dd, J = 18.3, 5.1 Hz, 1H, 1-Hb), 2.77 (d, J = 18.1 Hz, 1H, 4-Hb), 2.64 (dd, J = 18.3, 7.3 Hz, 1H,  
1-Ha), 2.56 (d, J = 18.1 Hz, 1H, 4-Ha), 1.18 (s, 3H, 3-CH3); 
13C NMR (125 MHz, DMSO-d6): δ 183.39 
(C-8), 176.35 (C-5), 161.31 (C-10), 160.38 (C-6), 159.67 (C-9), 138.88 (C-9a), 136.33 (C-4a), 109.47 
(C-7), 108.97 (C-10a), 106.85 (C-8a), 70.12 (C-2), 68.81 (C-3), 56.95 (6-OMe), 35.72 (C-4),   
29.91 (C-1), 25.39 (3-CH3); EIMS m/z 320 [M]
+ (100), 302 (41), 287 (30), 259 (61), 247 (96),   
234 (20), 219 (45), 205 (10). 
Nigrosporin B (3). Yellow solid (MeOH); mp: >300 °C; [α]
25 
D  +131.4 (c 1.75 × 10
−4, MeOH);  
1H NMR (400 MHz, DMSO-d6):  δ 12.67 (s, 1H, 9-OH), 7.26 (s, 1H, 10-H), 6.29 (s, 1H, 7-H),   
4.76 (d, J = 3.6 Hz, 1H, 2-OH), 4.39 (s, 1H, 3-OH), 3.88 (s, 3H, 6-OMe), 3.66 (m, 1H, 2-H), 2.93  Mar. Drugs 2012, 10  
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(d, J = 17.5 Hz, 1H, 4-Hb), 2.85 (dd, J = 18.4, 4.9 Hz, 1H, 1-Hb), 2.77 (d, J = 17.5 Hz, 1H, 4-Ha), 2.69 
(dd, J = 18.4, 7.1 Hz, 1H, 4-Ha), 1.17 (s, 3H, 3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 190.76 (C-8), 
178.79 (C-5), 161.11 (C-6), 158.31 (C-9), 144.01 (C-4a), 131.70 (C-9a), 127.95 (C-10a), 119.37   
(C-10), 110.65 (C-8a), 109.33 (C-7), 70.51 (C-2), 69.41 (C-3), 56.78 (6-OMe), 41.67 (C-4), 29.75  
(C-1), 25.07 (3-CH3); EIMS m/z 304 [M]
+ (34), 286 (85), 271 (100), 257 (57), 243 (94), 229 (45), 215 
(54), 201 (23). 
Austrocortinin (4). Yellow solid (CH2Cl2); mp: 232–233 °C; 
1H NMR (400 MHz, CDCl3): δ 13.59 
(s, 1H, 8-OH), 13.47 (s, 1H, 5-OH), 8.25 (d, J  = 8.0 Hz, 1H, 1-H), 8.16 (m, 1H, 4-H), 7.64   
(d m, J = 8.0 Hz, 1H, 2-H), 6.72 (s, 1H, 7-H), 4.03 (s, 3H, 6-OMe), 2.57 (br s, 3H, 3-CH3); EIMS  
m/z 284 [M]
+ (100), 266 (28), 238 (23), 210 (22), 182 (8), 157 (5), 139 (6). 
3.3. Synthetic Methods of Compounds 
3.3.1. Synthesis of 2,3-O-(isopropylidene) Bostrycin (5) 
To a solution of 1 (50 mg, 0.149 mmol) in 10 mL of tetrahydrofuran was added   
2,2-dimethoxypropane (310 mg, 3.0 mmol) and p-toluenesulfonic acid (25.6 mg, 0.149 mmol). The 
reaction mixture was stirred for 20 h at room temperature. The reaction mixture was diluted with water 
(20 mL) and extracted with dichloromethane (3 × 50 mL). The combined organic phase was washed 
with saturated sodium chloride, dried over anhydrous magnesium sulfate, and concentrated in vacuo. 
The resulting residue was purified on a silica gel column using petroleum ether–dichloromethane   
(v/v 1:1) as eluent to obtain 48.5 mg of compound 5. Yield 90%; red solid (CH2Cl2); mp: 228–229 °C; 
IR (KBr): νmax = 3486, 3036, 2989, 2972, 2937, 2890, 1598, 1427, 1384 cm
−1; 
1H NMR (400 MHz, 
CDCl3) δ 13.18 (s, 1H, 9-OH), 12.60 (s, 1H, 10-OH), 6.18 (s, 1H, 7-H), 5.51 (d, J = 2.7 Hz, 1H, 1-H), 
4.41 (d, J = 2.7 Hz, 1H, 2-H), 3.93 (s, 3H, 6-OMe), 3.41 (d, J = 16.7 Hz, 1H, 4-Hb), 2.72 (d, J = 16.7 Hz, 
1H, 4-Ha), 1.64 (s, 3H, 3-CH3), 1.40 (s, 3H, 2′-CH3), 1.03 (s, 3H, 3′-CH3); EIMS m/z 376 [M]
+ (19), 
361 (8), 318 (83), 301 (33), 289 (100), 273 (43), 257 (24), 243 (16). 
3.3.2. Synthesis of 2,3-O-(3′-methylbut-2′-enyl) Bostrycin (6) 
To a solution of 1 (50 mg, 0.149 mmol) in 10 mL of tetrahydrofuran was added 3-methyl-2-butenal 
(37.5 mg, 0.45 mmol) and p-toluenesulfonic acid (25.6 mg, 0.149 mmol). The reaction mixture was 
stirred for 10 h at room temperature. The reaction mixture was diluted with water (20 mL) and 
extracted with dichloromethane (3 × 50 mL). The combined organic phase was washed with saturated 
sodium chloride, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting 
residue was purified on a silica gel column using dichloromethane as eluent to obtain 47.9 mg of 
compound 6. Yield 80%; red solid (CH2Cl2); mp: 200–201 °C; IR (KBr): νmax = 3522, 3083, 2962, 
2928, 2873, 1598, 1571, 1437, 1407, 1376 cm
−1; 
1H NMR (400 MHz, CDCl3) δ 13.09 (s, 1H, 9-OH), 
12.53 (s, 1H, 10-OH), 6.12 (s, 1H, 7-H), 5.50 (d, J = 7.6 Hz, 1H, 1′-H), 5.45 (d, J = 2.5 Hz, 1H, 1-H), 
4.72 (d septet, J  = 7.6, 1.2 Hz, 1H, 2′-H), 4.20 (d, J = 2.5 Hz, 1H, 2-H), 3.92 (s, 3H, 6-OMe),  
3.51 (d, J = 16.3 Hz, 1H, 4-Hb), 2.67 (d, J = 16.3 Hz, 1H, 4-Ha), 1.67 and 1.60 (d, J = 1.2 Hz, 4′-CH3 
and 5′-CH3), 1.57 (s, 3H, 3-CH3); 
13C NMR (100MHz, CDCl3): δ 186.45 (C-8), 180.60 (C-5), 160.69 
(C-6), 158.54 (C-10), 156.95 (C-9), 141.85 (C-3′), 138.10 (C-9a), 137.86 (C-4a), 120.51 (C-2′), 110.97 Mar. Drugs 2012, 10  
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(C-10a), 109.92 (C-7), 108.79 (C-8a), 97.27 (C-1′), 83.05 (C-2), 79.12 (C-3), 62.82 (C-1),   
56.77 (6-OMe), 31.27 (C-4), 26.34 (3-CH3), 25.73 and 18.39 (C-4′ and C-5′); EIMS m/z 402 [M]
+ (5), 
387 (2), 318 (100), 301 (42), 289 (96), 271 (39), 257 (26), 243 (19). 
3.3.3. Synthesis of 1-O-(hydroxymethyl)-2,3-O-(methylene) Bostrycin (7) 
To a solution of 1 (100 mg, 0.298 mmol) in 10 mL of tetrahydrofuran was added polyoxymethylene 
(45 mg) and p-toluenesulfonic acid (51.2 mg, 0.298 mmol). The reaction mixture was stirred for 10 h 
at room temperature. The reaction mixture was diluted with water (20 mL) and extracted with 
dichloromethane (3 × 50 mL). The combined organic phase was washed with saturated sodium 
chloride, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The resulting residue 
was purified on a silica gel column using dichloromethane–methanol (v/v 200:1) as eluent to obtain  
27 mg of compound 7. Yield 24%; red solid (CH2Cl2); mp: 233–234 °C; IR (KBr): νmax = 3519, 3040, 
2956, 2927, 2901, 2871, 1603, 1568, 1460, 1435, 1408 cm
−1;
 1H NMR (400 MHz, CDCl3): δ 13.23  
(s, 1H, 9-OH), 12.64 (s, 1H, 10-OH), 6.17 (s, 1H, 7-H), 5.23 (d, J  = 7.1 Hz, 1H, 1′-Hb), 5.19   
(d, J = 4.4 Hz, 1H, 2′-Hb), 5.12 (dd, J = 7.5, 1.6 Hz, 1H, 2-H), 5.07 (d, J = 4.4 Hz, 1H, 2′-Ha), 5.04  
(d, J = 7.1 Hz, 1H, 1′-Ha), 3.92 (s, 3H, 6-OMe), 3.63 (d, J = 7.5 Hz, 1H, 1-H), 3.18 (d, J = 18.9 Hz, 1H,  
4-Hb), 2.69 (dd, J = 18.9, 1.6 Hz, 1H, 4-Ha), 1.50 (s, 3H, 3-CH3); 
13C NMR (100 MHz, CDCl3):  
δ 185.53 (C-8), 179.56 (C-5), 160.47 (C-6), 159.42 and 159.38 (C-9 and C-10), 136.41 (C-9a), 135.98 
(C-4a), 110.53 (C-10a), 110.12 (C-7), 108.64 (C-8a), 93.69 and 91.57 (C-1′ and C-2′), 84.98 (C-2), 
75.52 (C-3), 70.64 (C-1), 56.71 (6-OMe), 36.47 (C-4), 26.25 (3-CH3); EIMS m/z 378 [M]
+ (86), 
348 (14), 330 (45), 300 (100), 272 (80), 257 (45), 229 (28), 203 (11). 
3.3.4. Synthesis of 2,3-O-(carbonyl) Bostrycin (8) 
To a solution of 1  (100 mg, 0.298 mmol) and pyridine (235 mg, 0.298 mmol) in 5 mL of 
dichloromethane at −10 °C was added a solution of triphosgene in 2 mL of dichloromethane dropwise. 
The reaction mixture was stirred for 30 min, and then a saturated aqueous solution of ammonium 
chloride (2 mL) was added. The reaction mixture was diluted with water (10 mL) and extracted with 
dichloromethane (3 × 50 mL). The combined organic phase was successively washed with dilute 
aqueous hydrochloric acid (2 M), water, saturated sodium chloride, dried over anhydrous magnesium 
sulfate, and concentrated in vacuo. The resulting residue was purified on a silica gel column using 
dichloromethane–methanol (v/v 200:1) as eluent to obtain 30.2 mg of compound 8. Yield 28%; red 
solid (MeOH); mp: 246–247 °C; IR (KBr): νmax = 3403, 3081, 2977, 2942, 2850, 1814, 1603, 1570, 
1435, 1411 cm
−1; 
1H NMR (400 MHz, DMSO-d6): δ 13.14 (s, 1H, 9-OH), 12.32 (s, 1H, 10-OH),  
6.45 (s, 1H, 7-H), 6.20 (d, J  = 4.1 Hz, 1H, 1-OH), 5.33 (dd, J  = 4.1, 2.9 Hz, 1H, 1-H), 4.88   
(d, J = 2.9 Hz, 1H, 2-H), 3.92 (s, 3H, 6-OMe), 3.54 (d, J = 16.5 Hz, 1H, 4-Hb), 2.81 (d, J = 16.5 Hz, 
1H, 4-Ha), 1.76 (s, 3H, 3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 188.35 (C-8), 182.04 (C-5), 161.05  
(C-6), 154.53 (C-10), 153.90 (C-9), 152.64 (C=O), 135.93 (C-9a), 134.16 (C-4a), 111.60 (C-10a), 
110.10 (C-7), 109.56 (C-8a), 82.59 (C-3), 81.25 (C-2), 59.75 (C-1), 57.11 (6-OMe), 29.89 (C-4), 27.21 
(3-CH3); EIMS m/z 362 [M]
+ (46), 318 (17), 300 (100), 282 (29), 254 (19), 229 (25), 216 (10), 
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3.3.5. General Procedure: Synthesis of Compounds 9–22 
To a solution of 1  (1 equiv, 50 mg, 0.149 mmol) in 10 mL of methanol was added the 
corresponding amine (5 equiv). The reaction mixture was stirred at room temperature until the starting 
material disappeared (with aniline and 4-methoxyaniline, the reaction mixture was heated to 50 °C). 
The solvent was removed under reduced pressure. The resulting residue was purified on a silica gel 
column using dichloromethane–methanol as eluent, and then a C18 reversed phase silica gel column 
using methanol–water as eluent to obtain the corresponding products. 
6-(Methylamino)-6-demethoxybostrycin (9). Yield 53.6%; red solid (MeOH); mp: 266–267 °C;   
IR (KBr): νmax = 3532, 3457, 3389, 3319, 2973, 2928, 2843, 2808, 1584, 1517, 1418 cm
−1; 
1H NMR  
(400 MHz, DMSO-d6): δ 14.47 (s, 1H, 9-OH), 12.32 (s, 1H, 10-OH), 8.02 (q, J = 5.0 Hz, 1H, NH), 
5.57 (s, 1H, 7-H), 5.14 (d, J = 4.8 Hz, 1H, 1-OH), 4.96 (d, J = 4.6 Hz, 1H, 2-OH), 4.75 (t, J = 4.8 Hz, 
1H, 1-H), 4.50 (s, 1H, 3-OH), 3.52 (t, J = 4.6 Hz, 1H, 2-H), 2.83 (d, J = 5.0 Hz, 3H, NHCH3), 2.72  
(d, J = 17.8 Hz, 1H, 4-Hb), 2.64 (d, J = 17.8 Hz, 1H, 4-Ha), 1.23 (s, 3H, 3-CH3); 
13C NMR (125 MHz, 
DMSO-d6): δ 185.83 (C-8), 183.20 (C-5), 155.33 and 155.22 (C-9 and C-10), 150.44 (C-6), 139.49  
(C-9a), 132.93 (C-4a), 109.60 (C-10a), 107.92 (C-8a), 98.58 (C-7), 76.38 (C-2), 69.36 (C-3), 68.56  
(C-1), 34.75 (C-4), 29.08 (NHCH3), 25.68 (3-CH3); EIMS m/z 335 [M]
+ (46), 317 (14), 288 (31), 
261 (65), 246 (11), 233 (100), 218 (23), 204 (8). 
6-(n-Propylamino)-6-demethoxybostrycin (10). Yield 50.2%; red solid (MeOH); mp: 210–211 °C; 
IR (KBr): νmax = 3555, 3439, 3385, 3280, 3085, 2966, 2934, 2907, 2876, 1581, 1510, 1433 cm
−1;  
1H NMR (400 MHz, DMSO-d6): δ 14.51 (s, 1H, 9-OH), 12.33 (s, 1H, 10-OH), 7.97 (br t, 1H, NH), 
5.67 (s, 1H, 7-H), 5.14 (d, J = 4.4 Hz, 1H, 1-OH), 4.95 (d, J = 4.2 Hz, 1H, 2-OH), 4.74 (t, J = 4.4 Hz, 
1H, 1-H), 4.49 (s, 1H, 3-OH), 3.51 (t, J = 4.2 Hz, 1H, 2-H), 3.18 (q, J = 7.3 Hz, 2H, 1′-CH2), 2.72  
(d, J = 17.8 Hz, 1H, 4-Hb), 2.64 (d, J = 17.8 Hz, 1H, 4-Ha), 1.60 (sextet, J = 7.4 Hz, 2H, 2′-CH2), 1.22 
(s, 3H, 3-CH3), 0.91 (t, J = 7.5 Hz, 3H, 3′-CH3); 
13C NMR (125 MHz, DMSO-d6): δ 185.87 (C-8), 
183.30 (C-5), 155.27 and 155.25 (C-9 and C-10), 149.57 (C-6), 139.53 (C-9a), 132.89 (C-4a), 109.63 
(C-10a), 107.83 (C-8a), 98.56 (C-7), 76.38 (C-2), 69.36 (C-3), 68.57 (C-1), 43.72 (C-1′), 34.74 (C-4), 
25.67 (3-CH3), 20.67 (C-2′), 11.26 (C-3′); EIMS m/z 363 [M]
+ (43), 345 (13), 316 (53), 302 (16), 
289 (83), 261 (61), 232 (100), 218 (30). 
6-(n-Butylamino)-6-demethoxybostrycin (11). Yield 48.5%; red solid (MeOH); mp: 236–237 °C; 
IR (KBr): νmax = 3559, 3427, 3283, 3090, 2956, 2932, 2872, 1579, 1510, 1443 cm
–1; 
1H NMR 
(500 MHz, DMSO-d6): δ 14.47 (s, 1H, 9-OH), 12.32 (s, 1H, 10-OH), 7.89 (t, J = 5.4 Hz, 1H, NH), 
5.65 (s, 1H, 7-H), 5.07 (d, J = 4.7 Hz, 1H, 1-OH), 4.88 (d, J = 4.8 Hz, 1H, 2-OH), 4.75 (t, J = 4.7 Hz, 
1H, 1-H), 4.43 (s, 1H, 3-OH), 3.52 (t, J = 4.8 Hz, 1H, 2-H), 3.21 (dt, J = 5.4, 7.5 Hz, 2H, 1′-CH2), 2.73  
(d, J = 17.8 Hz, 1H, 4-Hb), 2.65 (d, J = 17.8 Hz, 1H, 4-Ha), 1.57 (pentet, J = 7.5 Hz, 2H, 2′-CH2), 1.34 
(sextet, J = 7.3 Hz, 2H, 3′-CH2), 1.23 (s, 3H, 3-CH3), 0.91 (t, J = 7.5 Hz, 3H, 4′-CH3); 
13C NMR  
(125 MHz, DMSO-d6): δ 185.82 (C-8), 183.26 (C-5), 155.29 (C-9 and C-10), 149.53 (C-6), 139.52  
(C-9a), 132.91 (C-4a), 109.62 (C-10a), 107.83 (C-8a), 98.50 (C-7), 76.38 (C-2), 69.36 (C-3), 68.58  
(C-1), 41.80 (C-1′), 34.75 (C-4), 29.34 (C-2′), 25.67 (3-CH3), 19.60 (C-3′), 13.56 (C-4′); EIMS   
m/z 377 [M]
+ (43), 359 (18), 341 (21), 303 (98), 275 (70), 260 (24), 232 (100), 218 (35). Mar. Drugs 2012, 10  
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6-(n-Hexylamino)-6-demethoxybostrycin (12). Yield 45%; red solid (MeOH); mp: 203–204 °C; 
IR (KBr):  νmax = 3557, 3384, 3285, 3089, 2955, 2929, 2859, 1578, 1512, 1436 cm
−1; 
1H NMR 
(400 MHz, DMSO-d6): δ 14.47 (s, 1H, 9-OH), 12.33 (s, 1H, 10-OH), 7.91 (t, J = 6.1 Hz, 1H, NH), 
5.65 (s, 1H, 7-H), 5.08 (d, J = 4.8 Hz, 1H, 1-OH), 4.89 (d, J = 4.6 Hz, 1H, 3-OH), 4.75 (t, J = 4.8 Hz, 
1H, 1-H), 4.44 (s, 1H, 3-OH), 3.52 (t, J = 4.6 Hz, 1H, 2-H), 3.21 (dt, J = 6.1, 7.0 Hz, 2H, 1′-CH2), 2.73 
(d, J = 17.8 Hz, 1H, 4-Hb), 2.65 (d, J = 17.8 Hz, 1H, 4-Ha), 1.58 (pentet, J = 7.0 Hz, 2H, 2′-CH2), 
1.37–1.26 (m, 6H, 3′, 4′ and 5′-CH2), 1.23 (s, 3H, 3-CH3), 0.87 (t, J = 7.1 Hz, 3H, 6′-CH3); 
13C NMR 
(100 MHz, DMSO-d6): δ 185.90 (C-8), 183.36 (C-5), 155.31 and 155.27 (C-9 and C-10), 149.55 (C-6), 
139.58 (C-9a), 132.92 (C-4a), 109.67 (C-10a), 107.87 (C-8a), 98.54 (C-7), 76.41 (C-2), 69.39 (C-3), 
68.60 (C-1), 42.11 (C-1′), 34.77 (C-4), 30.87 (C-2′), 27.23 and 26.07 (C-3′ and C-4′), 25.70 (3-CH3), 
21.97 (C-5′), 13.82 (C-6′); EIMS m/z 405 [M]
+ (29), 387 (10), 358 (39), 331 (85), 303 (67), 382 (30), 
323 (100), 218 (32). 
6-(2′-Hydroxyethylamino)-6-demethoxybostrycin (13). Yield 30%; red solid (MeOH); mp:   
202–203 °C; IR (KBr): νmax = 3374, 2968, 2924, 2898, 2857, 1587, 1518, 1439, 1402 cm
–1; 
1H NMR 
(500 MHz, DMSO-d6): δ 14.45 (s, 1H, 9-OH), 12.31 (s, 1H, 10-OH), 7.70 (t, J = 6.0 Hz, 1H, NH), 
5.73 (s, 1H, 7-H), 5.12 (d, J = 4.6 Hz, 1H, 1-OH), 4.92 (d, J = 4.4 Hz, 1H, 2-OH), 4.89 (t, J = 6.0 Hz, 
1H, 2′-OH), 4.74 (t, J = 4.6 Hz, 1H, 1-H), 4.46 (s, 1H, 3-OH), 3.61 (q, J = 6.0 Hz, 2H, 2′-CH2), 3.51  
(t, J = 4.4 Hz, 1H, 2-H), 3.29 (q, J = 6.0 Hz, 2H, 1′-CH2), 2.72 (d, J = 17.8 Hz, 1H, 4-Hb), 2.65  
(d, J = 17.8 Hz, 1H, 4-Ha), 1.22 (s, 3H, 3-CH3); 
13C NMR (125 MHz, DMSO-d6): δ 185.92 (C-8), 
183.03 (C-5), 155.40 (C-9 and C-10), 149.79 (C-6), 139.56 (C-9a), 133.08 (C-4a), 109.55 (C-10a), 
107.81 (C-8a), 98.95 (C-7), 76.38 (C-2), 69.36 (C-3), 68.58 (C-1), 58.41 (C-2′), 44.81 (C-1′), 34.78  
(C-4), 25.68 (3-CH3); EIMS m/z 365 [M]
+ (8), 349 (24), 327 (13), 314 (100), 298 (39), 282 (73), 
276 (16), 232 (24). 
6-[(2″-Hydroxyethoxy)ethylamino]-6-demethoxybostrycin (14). Yield 40.2%; red solid (MeOH); 
mp: 112–113 °C; IR (KBr): νmax = 3376, 2973, 2922, 2872, 1584, 1516, 1439, 1373 cm
−1; 
1H NMR 
(400 MHz, DMSO-d6): δ 14.38 (s, 1H, 9-OH), 12.30 (s, 1H, 10-OH), 7.68 (t, J = 5.6 Hz, 1H, NH), 
5.74 (s, 1H, 7-H), 5.14 (d, J = 4.8 Hz, 1H, 1-OH), 4.94 (d, J = 4.6 Hz, 1H, 2-OH), 4.75 (t, J = 4.8 Hz, 
1H, 1-H), 4.68 (t, J = 5.2 Hz, 1H, 2″-OH), 4.50 (s, 1H, 3-OH), 3.65 (t, J = 5.6 Hz, 2H, 1″-CH2),  
3.58–3.50 (m, 5H, 2-H, 2′-CH2 and 2″-CH2), 3.40 (q, J = 5.6 Hz, 2H, 1′-CH2), 2.74 (d, J = 17.8 Hz, 1H, 
4-Hb), 2.65 (d, J = 17.8 Hz, 1H, 4-Ha), 1.24 (s, 3H, 3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 186.59 
(C-8), 183.63 (C-5), 155.87 and 155.84 (C-9 and C-10), 150.12 (C-6), 140.09 (C-9a), 133.61 (C-4a), 
110.09 (C-10a), 108.34 (C-8a), 99.65 (C-7), 76.92 (C-2), 72.60 (C-2′), 69.96 (C-3), 69.12 (C-1), 67.93 
(C-1″), 60.65 (C-2″), 42.65 (C-1′), 35.29 (C-4), 26.16 (3-CH3); EIMS m/z 409 [M]
+ (2), 389 (24), 
373 (4), 357 (5), 327 (9), 314 (100), 300 (27), 282 (31). 
6-(Phenylamino)-6-demethoxybostrycin (15). Yield 60.4%; red solid (MeOH); mp: 226–227 °C; 
IR (KBr): νmax = 3576, 3560, 3409, 3248, 3037, 2968, 2919, 2901, 2850, 1587, 1572, 1521, 1444 cm
−1;  
1H NMR (500 MHz, DMSO-d6): δ 14.16 (s, 1H, 9-OH), 12.47 (s, 1H, 10-OH), 9.50 (br s, 1H, NH), 
7.51–7.28 (m, 5H, Ar-H), 6.07 (s, 1H, 7-H), 5.13 (br s, 1H, 1-OH), 4.91 (d, J = 4.5 Hz, 1H, 2-OH), 
4.81 (br t, 1H, 1-H), 4.45 (s, 1H, 3-OH), 3.57 (t, J = 4.6 Hz, 1H, 2-H), 2.80 (d, J = 17.9 Hz, 1H, 4-Hb), 
2.72 (d, J = 17.9 Hz, 1H, 4-Ha), 1.28 (s, 3H, 3-CH3); 
13C NMR (125 MHz, DMSO-d6): δ 186.46 (C-8), 
182.83 (C-5), 155.87 and 155.73 (C-9 and C-10), 147.33 (C-6), 139.49 (C-9a), 137.65 (C-1′), 133.97 Mar. Drugs 2012, 10  
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(C-4a), 129.27 (C-3′ and C-5′), 125.63 (C-4′), 123.91 (C-2′ and C-6′), 109.63 (C-10a), 107.84 (C-8a), 
101.33 (C-7), 76.40 (C-2), 69.36 (C-3), 68.51 (C-1), 34.86 (C-4), 25.68 (3-CH3); EIMS m/z 397 [M]
+ 
(20), 377 (45), 361 (28), 345 (27), 324 (53), 295 (100), 280 (14), 266 (4). 
6-(p-Methoxyphenylamino)-6-demethoxybostrycin (16). Yield 50.1%; red solid (MeOH); mp:   
202–203 °C; IR (KBr): νmax = 3379, 3260, 3032, 2964, 2921, 2838, 1585, 1522, 1440, 1418 cm
−1;  
1H NMR (400 MHz, DMSO-d6): δ 14.22 (s, 1H, 9-OH), 12.43 (s, 1H, 10-OH), 9.43 (br s, 1H, NH), 
7.33 (d, J = 8.6 Hz, 2H, Ar-H), 7.05 (br d, J = 8.6 Hz, 2H, Ar-H), 5.88 (s, 1H, 7-H), 5.11 (br s, 1H,  
1-OH), 4.91 (br s, 1H, 2-OH), 4.79 (br t, 1H, 1-H), 4.46 (s, 1H, 3-OH), 3.81 (s, 3H, 4′-OMe), 3.56  
(br t, 1H, 2-H), 2.79 (d, J = 17.9 Hz, 1H, 4-Hb), 2.70 (d, J = 17.9 Hz, 1H, 4-Ha), 1.27 (s, 3H, 3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 186.55 (C-8), 183.34 (C-5), 157.25 (C-4′), 155.58 and 155.51 (C-9 
and C-10), 148.02 (C-6), 139.60 (C-9a), 133.67 (C-4a), 130.22 (C-1′), 125.83 (C-2′ and C-6′), 114.58 
(C-3′ and C-5′), 109.75 (C-10a), 107.95 (C-8a), 100.50 (C-7), 76.47 (C-2), 69.45 (C-3), 68.58 (C-1), 
55.34 (4′-OMe), 34.89 (C-4), 25.76 (3-CH3); EIMS m/z 427 [M]
+ (29), 407 (74), 392 (53), 360 (44), 
325 (41), 310 (33), 284 (18), 263 (100). 
6-(Benzylamino)-6-demethoxybostrycin (17). Yield 52.6%; red solid (MeOH); mp: 153–154 °C; 
IR (KBr): νmax = 3384, 3064, 2971, 2927, 2907, 1581, 1513, 1438, 1373 cm
−1; 
1H NMR (400 MHz, 
DMSO-d6): δ 14.30 (s, 1H, 9-OH), 12.36 (s, 1H, 10-OH), 8.51 (t, J = 6.4 Hz, 1H, NH), 7.36–7.25  
(m, 5H, Ar-H), 5.58 (s, 1H, 7-H), 5.09 (d, J = 4.8 Hz, 1H, 1-OH), 4.90 (d, J = 4.6 Hz, 1H, 2-OH), 4.74  
(t, J = 4.8 Hz, 1H, 1-H), 4.49 (d, J = 6.4 Hz, 2H, NHCH2Ph), 4.44 (s, 1H, 3-OH), 3.52 (t, J = 4.6 Hz, 
1H, 2-H), 2.74 (d, J = 17.9 Hz, 1H, 4-Hb), 2.66 (d, J = 17.9 Hz, 1H, 4-Ha), 1.23 (s, 3H, 3-CH3);  
13C NMR (100 MHz, DMSO-d6): δ 185.98 (C-8), 183.29 (C-5), 155.46 and 155.38 (C-9 and C-10), 
149.54 (C-6), 139.57 (C-9a), 137.08 (C-1′), 133.24 (C-4a), 128.49 (C-3′ and C-5′), 127.16 and 127.12 
(C-2′, C-4′ and C-6′), 109.67 (C-10a), 107.79 (C-8a), 99.84 (C-7), 76.41 (C-2), 69.38 (C-3), 68.56  
(C-1), 45.25 (NHCH2), 34.79 (C-4), 25.70 (3-CH3); EIMS m/z 411 [M]
+ (4), 391 (10), 359 (12), 
337 (13), 302 (23), 284 (11), 218 (19), 204 (5), 91 (100). 
6-(p-Methoxybenzylamino)-6-demethoxybostrycin (18). Yield 55.3%; red solid (MeOH); mp:   
149–150 °C; IR (KBr): νmax = 3375, 3072, 2968, 2932, 2912, 2837, 1581, 1513, 1438, 1399 cm
−1;  
1H NMR (400 MHz, DMSO-d6): δ 14.33 (s, 1H, 9-OH), 12.35 (s, 1H, 10-OH), 8.47 (t, J = 6.4 Hz, 1H, 
NH), 7.32–6.88 (m, 4H, Ar-H), 5.59 (s, 1H, 7-H), 5.10 (d, J = 4.8 Hz, 1H, 1-OH), 4.91 (d, J = 4.6 Hz, 
1H, 2-OH), 4.74 (t, J = 4.8 Hz, 1H, 1-H), 4.45 (s, 1H, 3-OH), 4.41 (d, J = 6.4 Hz, 2H, NHCH2Ph), 3.73 
(s, 3H, 4′-OMe), 3.51 (t, J = 4.6 Hz, 1H, 2-H), 2.73 (d, J = 17.8 Hz, 1H, 4-Hb), 2.65 (d, J = 17.8 Hz, 
1H, 4-Ha), 1.22 (s, 3H, 3-CH3); 
13C NMR (100 MHz, DMSO-d6):  δ 185.94 (C-8), 183.37 (C-5),   
158.44 (C-4′), 155.45 and 155.35 (C-9 and C-10), 149.40 (C-6), 139.59 (C-9a), 133.20 (C-4a), 128.89 
and 128.55 (C-1′, C-2′ and C-6′), 113.91 (C-3′ and C-5′), 109.66 (C-10a), 107.80 (C-8a), 99.74 (C-7), 
76.42 (C-2), 69.40 (C-3), 68.58 (C-1), 55.02 (4′-OMe), 44.74 (NHCH2), 34.80 (C-4), 25.72 (3-CH3); 
EIMS m/z 441 [M]
+ (2), 425 (3), 407 (2), 389 (1), 320 (3), 302 (2), 274 (1), 232 (4), 121 (100). 
6-(p-Fluorobenzylamino)-6-demethoxybostrycin (19). Yield 43.2%; red solid (MeOH); mp:   
147–148 °C; IR (KBr): νmax = 3376, 3076, 2971, 2928, 2858, 1582, 1510, 1442, 1420 cm
–1; 
1H NMR 
(400 MHz, DMSO-d6): δ 14.29 (s, 1H, 9-OH), 12.35 (s, 1H, 10-OH), 8.49 (t, J = 6.4 Hz, 1H, NH), 
7.45–7.14 (m, 4H, Ar-H), 5.60 (s, 1H, 7-H), 5.09 (d, J = 4.7 Hz, 1H, 1-OH), 4.90 (d, J = 4.8 Hz, 1H,  Mar. Drugs 2012, 10  
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2-OH), 4.74 (t, J = 4.7 Hz, 1H, 1-H), 4.47 (d, J = 6.4 Hz, 2H, NHCH2Ph), 4.44 (s, 1H, 3-OH), 3.52  
(t, J = 4.8 Hz, 1H, 2-H), 2.74 (d, J = 17.8 Hz, 1H, 4-Hb), 2.65 (d, J = 17.8 Hz, 1H, 4-Ha), 1.23 (s, 3H, 
3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 186.02 (C-8), 183.26 (C-5), 161.31 (C-4′), 155.46 and 
155.36 (C-9 and C-10), 149.42 (C-6), 139.55 (C-9a), 133.26 (C-4a), 129.25 and 129.17 (C-1′, C-2′ and 
C-6′), 115.21 (C-3′ and C-5′), 109.66 (C-10a), 107.78 (C-8a), 99.84 (C-7), 76.41 (C-2), 69.38 (C-3), 
68.56 (C-1), 44.48 (NHCH2), 34.78 (C-4), 25.69 (3-CH3); ESIMS m/z 428 [M − 1]
−. 
6-(Piperidin-1-yl)-6-demethoxybostrycin (20). Yield 55%; red solid (MeOH); mp: 199–200 °C; IR 
(KBr): νmax = 3557, 3399, 3054, 2928, 2855, 1597, 1576, 1548, 1447, 1429 cm
−1; 
1H NMR (400 MHz, 
DMSO-d6): δ 14.10 (s, 1H, 9-OH), 12.58 (s, 1H, 10-OH), 6.03 (s, 1H, 7-H), 5.08 (d, J = 4.9 Hz, 1H,  
1-OH), 4.88 (d, J = 4.7 Hz, 1H, 2-OH), 4.78 (t, J = 4.9 Hz, 1H, 1-H), 4.42 (s, 1H, 3-OH), 3.58 (br s, 
4H, 2′-CH2 and 6′-CH2), 3.55 (t, J = 4.7 Hz, 1H, 2-H), 2.76 (d, J = 17.9 Hz, 1H, 4-Hb), 2.67 (d,  
J = 17.9 Hz, 1H, 4-Ha), 1.68 (br s, 6H, 3′-CH2, 4′-CH2 and 5′-CH2), 1.25 (s, 3H, 3-CH3); 
13C NMR  
(100 MHz, DMSO-d6): δ 185.33 (C-8), 184.27 (C-5), 156.12 and 155.91 (C-9 and C-10), 153.93 (C-6), 
138.50 (C-9a), 134.27 (C-4a), 111.14 (C-10a), 109.30 (C-7), 108.02 (C-8a), 76.45 (C-2), 69.45 (C-3), 
68.50 (C-1), 50.40 (C-2′ and C-6′), 35.00 (C-4), 25.75 (3-CH3), 25.46 (C-3′ and C-5′), 23.67 (C-4′); 
EIMS m/z 389 [M]
+ (37), 371 (30), 353 (17), 316 (100), 300 (12), 286 (24), 258 (10), 242 (9). 
6-(4′-Methylpiperidin-1-yl)-6-demethoxybostrycin (21). Yield 56.7%; red solid (MeOH); mp:   
162–163 °C; IR (KBr): νmax = 3559, 3408, 3055, 2948, 2927, 2855, 1597, 1580, 1550, 1451,   
1432 cm
−1; 
1H NMR (400 MHz, DMSO-d6): δ 14.10 (s, 1H, 9-OH), 12.59 (s, 1H, 10-OH), 6.04 (s, 1H, 
7-H), 5.09 (d, J = 4.8 Hz, 1H, 1-OH), 4.88 (d, J = 4.6 Hz, 1H, 2-OH), 4.78 (t, J = 4.8 Hz, 1H, 1-H), 
4.42 (s, 1H, 3-OH), 4.13 (m, 2H, 2′-Hb and 6′-Hb), 3.55 (t, J = 4.6 Hz, 1H, 2-H), 3.05 (m, 2H, 2′-Ha 
and 6′-Ha), 2.76 (d, J = 17.9 Hz, 1H, 4-Hb), 2.68 (d, J = 17.9 Hz, 1H, 4-Ha), 1.71 (m, 1H, 4′-H), 1.70 
(m, 2H, 3′-Hb and 5′-Hb), 1.27 (m, 2H, 3′-Ha and 5′-Ha), 1.26 (s, 3H, 3-CH3), 0.97 (d, J = 6.1 Hz, 3H,  
4′-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 185.13 (C-8), 184.04 (C-5), 156.33 and 156.05 (C-9 and 
C-10), 153.83 (C-6), 138.48 (C-9a), 134.32 (C-4a), 111.11 (C-10a), 109.46 (C-7), 107.99 (C-8a), 
76.43 (C-2), 69.42 (C-3), 68.50 (C-1), 49.63 and 49.56 (C-2′ and C-6′), 34.99 (C-4), 33.61 and 33.52 
(C-3′ and C-5′), 29.99 (C-4′), 25.71 (3-CH3), 21.41 (4′-CH3); EIMS m/z 403 [M]
+ (33), 385 (34), 
367 (50), 330 (100), 314 (31), 300 (28), 286 (20), 270 (15). 
6-(4′-Phenylpiperidin-1-yl)-6-demethoxybostrycin (22). Yield 45.6%; red solid (MeOH); mp:   
221–222 °C; IR (KBr): νmax = 3538, 3397, 3033, 2956, 2933, 2900, 2870, 1570, 1539, 1495,   
1455 cm
−1; 
1H NMR (400 MHz, DMSO-d6): δ 14.07 (s, 1H, 9-OH), 12.60 (s, 1H, 10-OH), 7.35–7.26 
(m, 4H, Ar-H), 7.21 (m, 1H, Ar-H), 6.10 (s, 1H, 7-H), 5.12 (d, J  = 4.7 Hz, 1H, 1-OH), 4.90   
(d, J = 4.8 Hz, 1H, 2-OH), 4.77 (t, J = 4.7 Hz, 1H, 1-H), 4.44 (s, 1H, 3-OH), 4.27 (m, 2H, 2′-Hb and  
6′-Hb), 3.53 (t, J  = 4.8 Hz, 1H, 2-H), 3.15 (m, 2H, 2′-Ha and 6′-Ha), 2.83 (m, 1H, 4′-H), 2.75   
(d, J = 17.9 Hz, 1H, 4-Hb), 2.66 (d, J = 17.9 Hz, 1H, 4-Ha), 1.91–1.76 (m, 4H, 3′-CH2 and 5′-CH2), 
1.24 (s, 3H, 3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 185.24 (C-8), 184.04 (C-5), 156.35 and 
156.12 (C-9 and C-10), 153.80 (C-6), 145.33 (C-1″), 138.53 (C-9a), 134.39 (C-4a), 128.38, 126.67 and 
126.19 (C-2″, C-3″, C-4″, C-5″ and C-6″), 111.12 (C-10a), 109.84 (C-7), 108.01 (C-8a), 76.43 (C-2), 
69.42 (C-3), 68.49 (C-1), 50.00 and 49.92 (C-2′ and C-6′), 41.32 (C-4′), 34.99 (C-4), 32.77 and 32.66 
(C-3′ and C-5′), 25.71 (3-CH3); EIMS m/z 465 [M]
+ (53), 445 (85), 429 (91), 413 (66), 392 (100), 
376 (12), 362 (16), 328 (62). Mar. Drugs 2012, 10  
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3.3.6. General Procedure: Synthesis of Compounds 23–29 
To a solution of 1 (1 equiv, 50 mg, 0.149 mmol) and triethylamine (8 equiv) in 10 mL of methanol 
was added the corresponding thiol (4 equiv). The reaction mixture was stirred at 0–5 °C until the 
starting material disappeared. The solvent was removed under reduced pressure. The resulting residue 
was purified on a silica gel column using dichloromethane–methanol as eluent, and then a C18 
reversed phase silica gel column using methanol–water as eluent to obtain the corresponding products. 
6,7-bis(Ethylthio)-6-demethoxybostrycin (23). Yield 60.4%; red solid (MeOH); mp: 180–181 °C; 
IR (KBr): νmax = 3561, 3379, 2968, 2923, 2865, 1604, 1572, 1486, 1447, 1426 cm
−1; 
1H NMR   
(400 MHz, DMSO-d6): δ 13.22 (s, 1H, 9-OH), 13.04 (s, 1H, 10-OH), 5.29 (d, J = 4.5 Hz, 1H, 1-OH), 
4.94 (d, J = 4.4 Hz, 1H, 2-OH), 4.75 (br t, 1H, 1-H), 4.49 (s, 1H, 3-OH), 3.53 (t, J = 4.4 Hz, 1H, 2-H), 
3.30–3.24 (m, 4H, 1′-CH2 and 1″-CH2), 2.74 (d, J = 18.5 Hz, 1H, 4-Hb), 2.67 (d, J = 18.5 Hz, 1H,  
4-Ha), 1.24–1.20 (m, 9H, 3-CH3, 2′-CH3 and 2″-CH3); 
13C NMR(100 MHz, DMSO-d6): δ 175.67   
(C-5), 175.55 (C-8), 164.61 (C-9), 163.16 (C-10), 145.75 (C-7), 145.07 (C-6), 138.58 and 138.54  
(C-4a and C-9a), 109.69 (C-10a), 109.32 (C-8a), 76.36 (C-2), 69.24 (C-3), 68.17 (C-1), 34.95 (C-4), 
28.70 and 28.64 (C-1′ and C-1″), 25.53 (3-CH3), 15.03 and 15.00 (C-2′ and C-2″); EIMS m/z 426 [M]
+ 
(8), 408 (10), 390 (3), 379 (21), 361 (100), 345 (28), 333 (79), 319 (22). 
6,7-bis(n-Butylthio)-6-demethoxybostrycin (24). Yield 51.2%; red solid (MeOH); mp: 124–125 °C; 
IR (KBr): νmax = 3551, 3400, 2958, 2929, 2871, 1599, 1532, 1431, 1377 cm
−1; 
1H NMR (400 MHz, 
DMSO-d6): δ 13.23 (s, 1H, 9-OH), 13.05 (s, 1H, 10-OH), 5.29 (br s, 1H, 1-OH), 4.94 (br s, 1H, 2-OH), 
4.75 (br s, 1H, 1-H), 4.49 (s, 1H, 3-OH), 3.53 (d, J = 4.4 Hz, 1H, 2-H), 3.29–3.20 (m, 4H, 1′-CH2 and 
1″-CH2), 2.73 (d, J = 18.4 Hz, 1H, 4-Hb), 2.67 (d, J = 18.4 Hz, 1H, 4-Ha), 1.58–1.46 (m, 4H, 2′-CH2 
and 2″-CH2), 1.39 (sextet, J  = 7.2 Hz, 4H, 3′-CH2 and 3″-CH2), 1.23 (s, 3H, 3-CH3), 0.86   
(br t, J = 7.2 Hz, 6H, 4′-CH3 and 4″-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 175.85 (C-5), 175.74 
(C-8), 164.55 (C-9), 163.07 (C-10), 146.16 (C-7), 145.52 (C-6), 138.59 and 138.55 (C-4a and C-9a), 
109.76 (C-10a), 109.37 (C-8a), 76.39 (C-2), 69.30 (C-3), 68.20 (C-1), 35.00 (C-4), 34.15 and 34.09 
(C-1′ and C-1″), 31.84 and 31.81 (C-2′ and C-2″), 25.61 (3-CH3), 21.10 (C-3′ and C-3″), 13.37 (C-4′ 
and C-4″); EIMS m/z 482 [M]
+ (2), 464 (3), 446 (8), 430 (2), 405 (28), 389 (100), 373 (31), 361 (14). 
6,7-bis(n-Hexylthio)-6-demethoxybostrycin (25). Yield 42.6%; red solid (MeOH); mp: 112–113°C; 
IR (KBr): νmax = 3545, 3370, 2956, 2925, 2854, 1598, 1433, 1419, 1379 cm
−1; 
1H NMR (400 MHz, 
DMSO-d6): δ 13.23 (s, 1H, 9-OH), 13.05 (s, 1H, 10-OH), 5.29 (d, J = 4.9 Hz, 1H, 1-OH), 4.94 (br s, 
1H, 2-OH), 4.75 (br t, 1H, 1-H), 4.49 (s, 1H, 3-OH), 3.53 (br d, 1H, 2-H), 3.29–3.19 (m, 4H, 1′-CH2 
and 1″-CH2), 2.73 (d, J = 18.4 Hz, 1H, 4-Hb), 2.67 (d, J = 18.4 Hz, 1H, 4-Ha), 1.59–1.47 (m, 4H,  
2′-CH2 and 2″-CH2), 1.44–1.30 (m, 4H, 3′-CH2 and 3″-CH2), 1.23 (br s, 11H, 3-CH3, 4′-CH2, 4″-CH2, 
5′-CH2 and 5″-CH2), 0.87–0.79 (m, 6H, 6′-CH3 and 6″-CH3); 
13C NMR (100 MHz, DMSO-d6):  
δ 175.87 (C-5), 175.75 (C-8), 164.52 (C-9), 163.03 (C-10), 146.17 (C-7), 145.53 (C-6), 138.58 and 
138.54 (C-4a and C-9a), 109.74 (C-10a), 109.36 (C-8a), 76.38 (C-2), 69.30 (C-3), 68.20 (C-1), 34.99 
(C-4), 34.48 and 34.41 (C-1′ and C-1″), 30.65, 29.71, 29.68 and 27.58 (C-2′, C-2″, C-3′, C-3″, C-4′ and 
C-4″), 25.60 (3-CH3), 21.91 (C-5′ and C-5″), 13.76 (C-6′ and C-6″); EIMS m/z 538 [M]
+ (4), 502 (4), 
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6,7-bis(2′-Hydroxyethylthio)-6-demethoxybostrycin (26). Yield 28.7%; red solid (MeOH); mp:   
156–158 °C; IR (KBr): νmax = 3560, 3405, 2960, 2928, 2874, 2862, 1606, 1573, 1488, 1426 cm
−1;  
1H NMR (400 MHz, DMSO-d6): δ 13.17 (s, 1H, 9-OH), 12.99 (s, 1H, 10-OH), 5.27 (d, J = 4.3 Hz, 1H, 
1-OH), 4.92 (br d, 1H, 2-OH), 4.89 and 4.88 (each br t, 1H, 2′-OH and 2″-OH), 4.77 (br t, 1H, 1-H), 
4.47 (s, 1H, 3-OH), 3.61 (q, J = 4.8 Hz, 4H, 2′-CH2 and 2″-CH2), 3.55 (br t, 1H, 2-H), 3.41–3.32 (m, 
4H, 1′-CH2 and 1″-CH2), 2.76 (d, J = 18.4 Hz, 1H, 4-Hb), 2.69 (d, J = 18.4 Hz, 1H, 4-Ha), 1.25 (s, 3H, 
3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 177.50 (C-5), 177.37 (C-8), 162.54 (C-9), 160.90 (C-10), 
146.93 (C-7), 146.41 (C-6), 138.10 and 138.02 (C-4a and C-9a), 109.91 (C-10a), 109.49 (C-8a), 76.45 
(C-2), 69.36 (C-3), 68.26 (C-1), 61.05 (C-2′ and C-2″), 37.13 and 37.09 (C-1′ and C-1″), 35.06 (C-4), 
25.68 (3-CH3); ESIMS m/z 457 [M − 1]
−. 
6,7-bis(3′-Hydroxy-n-propylthio)-6-demethoxybostrycin (27). Yield 32.5%; red solid (MeOH); mp: 
150–151 °C; IR (KBr): νmax = 3550, 3423, 2993, 2925, 2874, 2855, 1599, 1528, 1430, 1403, 1375 cm
−1; 
1H NMR (400 MHz, DMSO-d6): δ 13.20 (s, 1H, 9-OH), 13.03 (s, 1H, 10-OH), 5.25 (d, J = 4.3 Hz, 1H, 
1-OH), 4.90 (d, J = 4.2 Hz, 1H, 2-OH), 4.75 (br t, 1H, 1-H), 4.50–4.43 (m, 3H, 3′-OH, 3″-OH and  
3-OH), 3.52 (t, J = 4.2 Hz, 1H, 2-H), 3.47 (q, J = 6.4 Hz, 4H, 3′-CH2 and 3″-CH2), 3.36–3.28 (m, 4H, 
1′-CH2 and 1″-CH2), 2.74 (d, J = 18.4 Hz, 1H, 4-Hb), 2.67 (d, J = 18.4 Hz, 1H, 4-Ha), 1.68 (pentet,  
J = 6.4 Hz, 4H, 2′-CH2 and 2″-CH2), 1.23 (s, 3H, 3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 176.23 
(C-5), 176.12 (C-8), 164.14 (C-9), 162.61 (C-10), 146.32 (C-7), 145.73 (C-6), 138.51 and 138.48  
(C-4a and C-9a), 109.85 (C-10a), 109.45 (C-8a), 76.43 (C-2), 69.35 (C-3), 68.23 (C-1), 59.09 (C-3′ 
and C-3″), 35.04 (C-4), 33.07 and 33.04 (C-1′ and C-1″), 31.46 and 31.40 (C-2′ and C-2″), 25.67  
(3-CH3); ESIMS m/z 485 [M − 1]
−. 
6,7-(Ethan-1′,2′-yl-dithio)-6-demethoxybostrycin (28). Yield 24.8%; red solid (MeOH); mp: >300 °C; 
IR (KBr): νmax = 3417, 2966, 2925, 2857, 1588, 1513, 1436, 1375 cm
−1; 
1H NMR (400 MHz,   
DMSO-d6): δ 12.84 (s, 1H, 9-OH), 12.67 (s, 1H, 10-OH), 5.26 (br s, 1H, 1-OH), 4.94 (d, J = 4.4 Hz, 
1H, 2-OH), 4.75 (d, J = 4.6 Hz, 1H, 1-H), 4.49 (s, 1H, 3-OH), 3.53 (t, J = 4.4 Hz, 1H, 2-H), 3.35 (br s, 
4H, 1′-CH2 and 2′-CH2), 2.75 (d, J = 18.2 Hz, 1H, 4-Hb), 2.68 (d, J = 18.2 Hz, 1H, 4-Ha), 1.23 (s, 3H, 
3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 180.54 and 180.42 (C-5 and C-8), 157.65 (C-9), 155.72 
(C-10), 140.74 (C-7), 140.20 (C-6), 137.39 and 137.23 (C-4a and C-9a), 108.17 (C-10a), 107.66   
(C-8a), 76.43 (C-2), 69.29 (C-3), 68.30 (C-1), 35.11 (C-4), 26.17 and 26.08 (C-1′ and C-2′), 25.67  
(3-CH3); EIMS m/z 396 [M]
+ (6), 376 (28), 360 (100), 344 (47), 332 (22), 307 (23), 294 (13), 279 (12). 
6,7-(Butan-2′,3′-yl-dithio)-6-demethoxybostrycin (29). Yield 63.5%; red solid (MeOH); mp:   
146–147 °C; IR (KBr): νmax = 3446, 3250, 2960, 2916, 2859, 1589, 1516, 1441, 1418 cm
−1; 
1H NMR 
(400 MHz, DMSO-d6): δ 12.85 (s, 1H, 9-OH), 12.69 (s, 1H, 10-OH), 5.22 (br s, 1H, 1-OH), 4.91  
(d, J = 4.6 Hz, 1H, 2-OH), 4.75 (d, J = 4.5 Hz, 1H, 1-H), 4.45 (s, 1H, 3-OH), 3.67 and 3.48 (each m, 
1H, 2′-CH and 3′-CH), 3.54 (t, J  = 4.6 Hz, 1H, 2-H), 2.75 (d, J  = 18.3 Hz, 1H, 4-Hb), 2.68   
(d, J = 18.3 Hz, 1H, 4-Ha), 1.32 and 1.30 (each d, J = 6.2 Hz, 3H, 1′-CH3 and 4′-CH3), 1.23 (s, 3H,  
3-CH3); 
13C NMR (100 MHz, DMSO-d6): δ 180.69 and 180.66 (C-5 and C-8), 157.58 (C-9), 155.64 
(C-10), 139.83 (C-7), 138.71 (C-6), 137.39 and 137.18 (C-4a and C-9a), 108.38 (C-10a), 107.86   
(C-8a), 76.46 (C-2), 69.33 (C-3), 68.32 (C-1), 35.11 (C-4), 25.70 (3-CH3), 22.99 and 22.89 (C-2′ and 
C-3′), 17.60 (C-1′ and C-4′); EIMS m/z 424 [M]
+ (8), 406 (5), 388 (3), 351 (29), 335 (5), 322 (9), 
307 (5), 295 (13), 71 (100). Mar. Drugs 2012, 10  
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3.4. Antitumor Activity in Vitro 
3.4.1. Cell Culture 
MCF-7, MDA-MB-435, A549, HepG2 and HCT-116 cells were cultured in Dulbecco’s 
modification Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal 
bovine serum (FBS, Hyclone, Logan, UT, USA), 2 mM L-glutamine, 100 μg/mL streptomycin and  
100 U/mL penicillin (Invitrogen). MCF-10A cells were cultured in keratinocyte serum free medium 
(KSFM) supplemented with 0.1–0.2 ng/mL human recombinant epidermal growth factor and   
20–30 μg/mL bovine pituitary extract (Invitrogen). The cells were incubated at 37 °C in a humidified 
atmosphere with 5% CO2. 
3.4.2. Assessment of Antitumor Activity by MTT Assay 
Cells were harvested during logarithmic growth phase and seeded in 96-well plates at a density of  
1 × 10
4 cells/mL, and cultured at 37 °C in a humidified incubator (5% CO2) for 24 h, followed by 
exposure to various concentrations of compounds tested for 48 h. Subsequently 20 μL of MTT 
(Genview, Houston, TX, USA) solution (5 mg/mL) was added to each well and mixed, the cells were 
then incubated for an additional 4 h. Culture supernatant was moved, 150 μL of DMSO (Sangon 
Biotech, Shanghai, China) was added to each well to fully dissolve the MTT-formazan crystals. Cell 
growth inhibition was determined by measuring the absorbance (Abs) at λ = 570 nm using a 
microplate reader and calculated according to the following equation:  
Growth inhibition = (1 − OD of treated cells/OD of control cells) × 100%  
The half maximal inhibitory concentrations (IC50) were obtained from liner regression analysis of 
the concentration-response curves plotted for each tested compound. 
4. Conclusions 
This paper has reported the synthesis and biological evaluation of a novel class of bostrycin 
derivatives against a panel of tumor cells along with one type of immortalized human breast epithelial 
cells. Encouragingly, some modified compounds displayed superior cytotoxicity over the parent 
compound bostrycin and equal anticancer potency to epirubicin which served as a reference anticancer 
drug. However, the majority of compounds also exhibited marked cytotoxicity towards MCF-10A cells. 
Preliminary SAR study indicated that the enhanced cytotoxicity was fulfilled by dioxylcarbonyl groups 
at C-2 and C-3 positions, tertiary amino groups at C-6 position and alkylthio groups at C-6 and C-7 
positions of the bostrycin. These positive results could serve as a valuable guideline for further 
research on the structural optimization, mechanism study and development of bostrycin derivatives as 
novel antitumor agents. Mar. Drugs 2012, 10  
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